Skip to content

Study · Case report or series · 2024

1 result

Liraglutide for the Treatment of Severe Hypoglycemia Following Total Pancreatectomy and Islet Autotransplantation.

Chan C, Hawthorne W, Pleass H, Holmes-Walker DJ

JCEM case reports24 Oct 2024Cited by 1 (Europe PMC)

PMID39450137 (opens in a new tab)PMCIDPMC11500716 (opens in a new tab)DOI10.1210/jcemcr/luae178 (opens in a new tab)PepBankPUB-39450137
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

Total pancreatectomy and islet autotransplantation (TPIAT) is an effective treatment for chronic and recurrent acute pancreatitis, and it provides a significant potential additional benefit of insulin independence. Spontaneous hypoglycemia in the absence of insulin therapy following TPIAT is a recognized complication, which has been attributed to lack of protective glucagon responses to hypoglycemia, following intrahepatic islet autotransplantation. We describe the use of liraglutide to treat spontaneous hypoglycemia following TPIAT. Continuous glucose monitoring was used to identify timing of hypoglycemia in relation to meals and monitor treatment effect. Liraglutide has been used for management of hypoglycemia following bariatric surgery, but, to our knowledge, this is the first application of its effective use to treat spontaneous severe hypoglycemia following TPIAT.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a case report of spontaneous severe hypoglycemia after total pancreatectomy and islet autotransplantation, liraglutide was reported as an effective treatment.

    In plain wordsIn a case report, liraglutide was described as effective for severe low blood sugar after pancreas removal with islet transplant.

    Peptide
    Liraglutide
    Outcome
    DecreaseSpontaneous severe hypoglycemia after TPIAT
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    this is the first application of its effective use to treat spontaneous severe hypoglycemia following TPIAT.
    1 context sentence
    Summary · context
    We describe the use of liraglutide to treat spontaneous hypoglycemia following TPIAT.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.